{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:53:45Z","timestamp":1781643225457,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Aims<\/jats:title>\n                    <jats:p>Retinal vein occlusion (RVO) is a common cause of vision loss, treated primarily with intravitreal anti-VEGF injections. This study aimed to investigate how the timing of treatment initiation affects visual acuity and retinal thickness outcomes in patients with branch (BRVO) and central retinal vein occlusion (CRVO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective observational study was conducted involving 86 patients diagnosed with RVO (54 BRVO, 32 CRVO) and treated with anti-VEGF therapy at a single UK centre. Patients were stratified into early (\u2264\u200928 days) and delayed (&gt;\u200928 days) treatment groups based on the time from diagnosis to first injection. Visual acuity (ETDRS letters) and central retinal thickness (\u00b5m) were recorded at diagnosis, after three loading doses, and at one year. Paired t-tests were used to assess changes over time. Associations between treatment timing and outcomes were evaluated using Spearman\u2019s rank correlation, while between-group comparisons were performed using Mann\u2013Whitney U and chi-square tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      BRVO patients had significant VA gains at three injections (mean\u2009+\u200913.2 letters,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and at one year (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0002), while CRVO patients showed a non-significant trend toward improvement (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.081). CRT reductions were significant in both CRVO and BRVO at three injections and at one year (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Earlier treatment (\u2264\u200928 days) was weakly correlated with greater CRT reduction in CRVO (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047), but no significant association was found between treatment timing and VA change or likelihood of &gt;\u200915-letter improvement in either group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While early treatment led to short-term visual and anatomical gains, long-term visual outcomes at one year were not significantly associated with treatment timing, suggesting other clinical and individual factors contribute to final prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-026-04667-2","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T12:02:17Z","timestamp":1773489737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Visual acuity and retinal thickness outcomes following anti-VEGF therapy in RVO: influence of early vs. delayed treatment"],"prefix":"10.1186","volume":"26","author":[{"given":"Lexzion","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blazej","family":"Staniszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Johnstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"4667_CR1","unstructured":"Blair K, Czyz CN, Central Retinal Vein O. Central retinal vein occlusion. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 May 1. PMID: 30252241."},{"key":"4667_CR2","doi-asserted-by":"publisher","unstructured":"Rosenblatt TR, Vail D, Saroj N, Boucher N, Moshfeghi DM, Moshfeghi AA. Increasing incidence and prevalence of common retinal diseases in retina practices across the United States. Ophthalmic Surg Lasers Imaging Retina. 2021;52(1):29\u201336. https:\/\/doi.org\/10.3928\/23258160-20201223-06. PMID: 33471912.","DOI":"10.3928\/23258160-20201223-06"},{"issue":"4","key":"4667_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/mt.2008.10","volume":"16","author":"PA Campochiaro","year":"2008","unstructured":"Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, Quinlan E, Zimmer-Galler I, Haller JA, Solomon SD, Sung JU, Hadi Y, Janjua KA, Jawed N, Choy DF, Arron JR. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther. 2008;16(4):791\u20139. https:\/\/doi.org\/10.1038\/mt.2008.10. Epub 2008 Feb 5. PMID: 18362932.","journal-title":"Mol Ther"},{"issue":"6","key":"4667_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","volume":"117","author":"PA Campochiaro","year":"2010","unstructured":"Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG. BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102\u2013e11121. Epub 2010 Apr 15. PMID: 20398941.","journal-title":"Ophthalmology"},{"issue":"6","key":"4667_CR5","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY. CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124\u2013e11331. Epub 2010 Apr 9. PMID: 20381871.","journal-title":"Ophthalmology"},{"key":"4667_CR6","doi-asserted-by":"publisher","unstructured":"Varma R, Bressler NM, Su\u00f1er I, Lee P, Dolan CM, Ward J, Colman S, Rubio RG, BRAVO and CRUISE Study Groups. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology. 2012;119(10):2108-18. https:\/\/doi.org\/10.1016\/j.ophtha.2012.05.017. Epub 2012 Jul 18. PMID: 22817833.","DOI":"10.1016\/j.ophtha.2012.05.017"},{"issue":"5","key":"4667_CR7","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41433-022-02007-4","volume":"36","author":"L Nicholson","year":"2022","unstructured":"Nicholson L, Talks SJ, Amoaku W, Talks K, Sivaprasad S. Retinal vein occlusion (RVO) guideline: executive summary. Eye (Lond). 2022;36(5):909\u201312. https:\/\/doi.org\/10.1038\/s41433-022-02007-4. Epub 2022 Mar 17. PMID: 35301458; PMCID: PMC9046155.","journal-title":"Eye (Lond)"},{"issue":"5","key":"4667_CR8","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.ophtha.2016.01.011","volume":"123","author":"M Larsen","year":"2016","unstructured":"Larsen M, Waldstein SM, Boscia F, Gerding H, Mon\u00e9s J, Tadayoni R, et al. Individualized Ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: Twelve-Month results of the CRYSTAL study. Ophthalmology. 2016;123(5):1101\u201311. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.011.","journal-title":"Ophthalmology"},{"issue":"2","key":"4667_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s10384-014-0305-9","volume":"58","author":"YH Yoon","year":"2014","unstructured":"Yoon YH, Kim HK, Yoon HS, Kang SW, Kim JG, Park KH, Jo YJ, Lee JY, Lee DH, Korean RVO, Study Group. Improved visual outcome with early treatment in macular edema secondary to retinal vein occlusions: 6-month results of a Korean RVO study. Jpn J Ophthalmol. 2014;58(2):146\u201354. https:\/\/doi.org\/10.1007\/s10384-014-0305-9. Epub 2014 Jan 31. PMID: 24477666.","journal-title":"Jpn J Ophthalmol"},{"key":"4667_CR10","doi-asserted-by":"publisher","first-page":"102449","DOI":"10.1016\/j.pdpdt.2021.102449","volume":"35","author":"MN Bulut","year":"2021","unstructured":"Bulut MN, S\u00f6nmez HS, G\u00f6k\u00e7e G, A\u011fa\u00e7kesen A, Bulut K, Hac\u0131saliho\u011flu A, Arsan A, \u015eim\u015fek \u015e. The impact of delayed anti-vascular endothelial growth factor treatment for retinal diseases during the COVID-19 lockdown. Photodiagnosis Photodyn Ther. 2021;35:102449. https:\/\/doi.org\/10.1016\/j.pdpdt.2021.102449. Epub 2021 Jul 24. PMID: 34314862; PMCID: PMC8305215.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"7","key":"4667_CR11","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s00417-021-05174-4","volume":"259","author":"LG Stone","year":"2021","unstructured":"Stone LG, Grinton ME, Talks JS. Delayed follow-up of medical retina patients due to COVID-19: impact on disease activity and visual acuity. Graefes Arch Clin Exp Ophthalmol. 2021;259(7):1773\u201380. https:\/\/doi.org\/10.1007\/s00417-021-05174-4. Epub 2021 May 11. PMID: 33977317; PMCID: PMC8112469.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4667_CR12","doi-asserted-by":"publisher","first-page":"4936924","DOI":"10.1155\/2017\/4936924","volume":"2017","author":"J Li","year":"2017","unstructured":"Li J, Paulus YM, Shuai Y, Fang W, Liu Q, Yuan S. New developments in the Classification, Pathogenesis, risk Factors, natural History, and treatment of branch retinal vein occlusion. J Ophthalmol. 2017;2017:4936924. https:\/\/doi.org\/10.1155\/2017\/4936924. Epub 2017 Mar 12. PMID: 28386476; PMCID: PMC5366235.","journal-title":"J Ophthalmol"},{"key":"4667_CR13","doi-asserted-by":"publisher","unstructured":"Hayreh SS, Rojas P, Podhajsky P, Montague P, Woolson RF. Ocular neovascularization with retinal vascular occlusion\u2014III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology. 1983;90(5):488\u2013506. https:\/\/doi.org\/10.1016\/s0161-6420(83)34542-5. PMID: 6192376.","DOI":"10.1016\/s0161-6420(83)34542-5"},{"key":"4667_CR14","doi-asserted-by":"publisher","unstructured":"Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology. 2011;118(1):119\u2013133.e1-2. https:\/\/doi.org\/10.1016\/j.ophtha.2010.04.019. Epub 2010 Aug 17. PMID: 20723991; PMCID: PMC2989417.","DOI":"10.1016\/j.ophtha.2010.04.019"},{"key":"4667_CR15","doi-asserted-by":"crossref","unstructured":"Nagasato D, et al. Factors associated with extremely poor visual outcomes in patients with central retinal vein occlusion. Sci Rep. 2020 Nov 12;10(1):19667. PubMed PMID: 33184484.","DOI":"10.1038\/s41598-020-76840-6"},{"issue":"1","key":"4667_CR16","doi-asserted-by":"publisher","first-page":"16974","DOI":"10.1038\/s41598-024-67925-7","volume":"14","author":"C Agata","year":"2024","unstructured":"Agata C, Aoki S, Kitamoto K, Azuma K, Fujino R, Inoue T, Obata R. Time to initiate anti-vascular endothelial growth factor therapy and visual outcome in central retinal vein occlusion. Sci Rep. 2024;14(1):16974. https:\/\/doi.org\/10.1038\/s41598-024-67925-7. PMID: 39043891; PMCID: PMC11266534.","journal-title":"Sci Rep"},{"issue":"9","key":"4667_CR17","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.oret.2020.11.010","volume":"5","author":"JG Light","year":"2021","unstructured":"Light JG, Tian J, Wenick AS. Outcomes in retinal vein occlusions presenting with poor visual acuity treated with Anti-Vascular endothelial growth factor therapy: prognosis and predictive factors. Ophthalmol Retina. 2021;5(9):888\u2013900. Epub 2020 Nov 20. PMID: 33227561.","journal-title":"Ophthalmol Retina"},{"issue":"12","key":"4667_CR18","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.oret.2025.05.025","volume":"9","author":"M Ip","year":"2025","unstructured":"Ip M, Modi Y, Fekrat S, Gibson K, Boucher N, Arrisi P, Ishii F, Liu Y, Paris LP, Fenech M, Chi GC. Treatment patterns and Long-term outcomes with anti-VEGF therapy for retinal vein occlusion: an analysis of the vestrum database. Ophthalmol Retina. 2025;9(12):1187\u201396. Epub 2025 May 27. PMID: 40441380.","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"4667_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41433-025-04089-2","volume":"40","author":"C Dinah","year":"2026","unstructured":"Dinah C, Dodds M, Lotery A, Salvatore S, Fletcher E, Lake AVR, Parker A, Paris Pereira L, Retiere AC, Saffar I, Arrisi P, United Kingdom Retinal Vein Occlusion Electronic Medical Records Users Group (UK RVO EMR Users Group), Chi GC. Treatment patterns and long-term outcomes in anti-VEGF-treated macular oedema secondary to retinal vein occlusion: a retrospective observational study. Eye (Lond). 2026;40(1):107\u201316. https:\/\/doi.org\/10.1038\/s41433-025-04089-2. Epub 2025 Nov 14. PMID: 41238745; PMCID: PMC12764885.","journal-title":"Eye (Lond)"},{"issue":"2","key":"4667_CR20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ophtha.2010.06.034","volume":"118","author":"IU Scott","year":"2011","unstructured":"Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Hartnett ME, Cohen G. Standard care versus corticosteroid for retinal vein occlusion study investigator Group. Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: standard care versus corticosteroid for retinal vein occlusion study report 10. Ophthalmology. 2011;118(2):345\u201352. PMID: 20926135; PMCID: PMC3020981.","journal-title":"Ophthalmology"},{"issue":"12","key":"4667_CR21","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1136\/bjophthalmol-2020-317337","volume":"105","author":"T Ciulla","year":"2021","unstructured":"Ciulla T, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes. Br J Ophthalmol. 2021;105(12):1696\u2013704. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317337. Epub 2020 Oct 14. PMID: 33055088; PMCID: PMC8639936.","journal-title":"Br J Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04667-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04667-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04667-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:07:06Z","timestamp":1781640426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04667-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4667"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04667-2","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted as a retrospective service evaluation using routinely collected and fully anonymised clinical data. Approval for data access and use was granted by the Caldicott Guardian via the Information Governance & Cyber Assurance team at NHS Tayside (Ref: IGTCAL-2025-032). In line with guidance from the UK Health Research Authority (HRA), this project did not require review by a Research Ethics Committee (REC), as it did not involve any change to standard patient care, randomisation, or prospective data collection. This determination aligns with the HRA\u2019s \u201cDefining Research\u201d guidance and online decision tool, which confirm that service evaluations using anonymised, routinely collected data fall outside the remit of NHS REC approval requirements (HRA Decision Tool:\n                      \n                      ). As the study used anonymised retrospective data with no patient contact or intervention, individual informed consent was not required under UK data protection law and HRA policy. All data were processed in accordance with institutional governance protocols and relevant data protection regulations, including the UK General Data Protection Regulation (UK GDPR) and the Data Protection Act 2018.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}